The lack of specificity of PSA as well as the risk of overdiagnosis of indolent cancers, has led to the development of personalized clinical prostate cancer risk calculators, which increasingly incorporate the findings of pre‐biopsy prostate MRI. The gene discussed is KLK3; the disease is prostate cancer.